Effect of an Estrogen-deficient State and Alendronate Therapy on Bone Loss Resulting from Experimental Periapical Lesions in Rats

Journal of Endodontics

Volumn 33, Issue 11, 2007, Pages 1304-1308

  Xiong, Haofei ^a   Peng, Bin ^a   Wei, Lili ^a   Zhang, Xiaolei ^a   Wang, Li ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Alendronate therapy; bone loss; estrogen deficient state; periapical lesions

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ESTROGEN;

ANIMAL; ARTICLE; FEMALE; METABOLISM; OSTEOLYSIS; OVARIECTOMY; OVARY; PATHOLOGY; PERIODONTITIS; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ALENDRONATE; ALVEOLAR BONE LOSS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; ESTROGENS; FEMALE; INJECTIONS, SUBCUTANEOUS; OVARIECTOMY; OVARY; PERIODONTITIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 35348932098     PISSN: 00992399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joen.2007.07.011     Document Type: Article

References (28)

1. Hofbauer L.C., Kühne C.A., and Viereck V. The OPG/RANKL/RANK system in metabolic bone disease. J Musculoskel Neuron Interact 4 (2004) 268-275
2. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 (2000) 115-137
3. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11 (1996) 1043-1051
4. Riggs B.L., Khosla S., and Melton L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13 (1998) 763-773
5. Jiang G., Matsumoto H., and Fujii A. Mandible bone loss in osteoporosis rats. J Bone Miner Metab 21 (2003) 388-395
6. Gilles J.A., Carnes D.L., Dallas M.R., et al. Oral bone loss is increased in ovariectomized rats. J Endod 23 (1997) 419-422
7. Duarte P.M., Goncalves P.F., Sallum A.W., et al. Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodont Res 39 (2004) 107-110
8. Seedor J.G., Quartucci H.A., and Thompson D.D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6 (1991) 339-346
9. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
10. Duarte P.M., de Assis D.R., Casati M.Z., et al. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol 75 (2004) 1196-1202
11. Lane N., Armitage G.C., Loomer P., et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 76 (2005) 1113-1122
12. Metzger Z., Klein H., Klein A., et al. Periapical lesion development in rats inhibited by dexamethasone. J Endod 28 (2002) 643-645
13. Lin S.K., Hong C.Y., Chang H.H., et al. Immunolocalization of macrophages and transforming growth factor-β1 in induced rat periapical lesions. J Endod 26 (2000) 335-340
14. Balto K., Mǔller R., Carrington D.C., et al. Quantification of periapical bone destruction in mice by micro-computed tomography. J Den Res 79 (2000) 35-40
15. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34 (1982) 285-290
16. Nociti Jr. F.H., Sallum A.W., Duarte P.M., et al. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: A histometric study. Int J Oral Maxillofac Implants 17 (2002) 786-792
17. Durate P.M., Goncalves P.F., Casati M.Z., et al. Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: a histometric study in rats. J Periodont Res 41 (2006) 541-546
18. Razmus T.F. Caries, periodontal disease, and periapical changes. Dent Clin North Am 38 (1994) 13-31
19. Suda T., Takahashi N., Udagawa N., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 (1999) 345-357
20. Takayanagi H., Ogasawara K., Hida S., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408 (2000) 600-605
21. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
22. Zhang X.L., and Peng B. Immunolocalization of receptor activator of NF kappa B ligand in rat periapical lesions. J Endod 31 (2005) 574-577
23. Chapurlat R.D., and Delmas P.D. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2 (2006) 211-219
24. Luckman S.P., Hughes D.E., Coxon F.P., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581-589
25. Benford H.L., McGowan N.W., Helfrich M.H., et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465-473
26. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod 31 (2005) 831-834
27. Sarathy A.P., Bourgeois Jr. S.L., Goodell G.G., et al. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31 (2005) 759-763
28. Aki S., Eskiyurt N., Akarimak U., et al. Gastroinstestinal side effect profile duo to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 44 (2003) 961-967